TerminatedPhase 3NCT02411084
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Adienne SA
- Principal Investigator
- Andrea Bacigalupo, MD
- Intervention
- Begelomab(biological)
- Enrollment
- 36 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2016 – 2017
Study locations (27)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Duke Cancer Center, Durham, North Carolina, United States
- The Ohio State University, Columbus, Ohio, United States
- Oregon Health & Science University, Portland, Oregon, United States
- Huntsman Cancer Center, University of Utah, Salt Lake City, Utah, United States
- Centre Hospitalier Universitaire de Grenoble, La Tronche, France
- Hospital Saint-Louis APHP (Hôpitaux Universitaires Sant-Louis), Paris, France
- Centre Hospitalier Lyon-Sud, Pierre-Bénite, France
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
- Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy
- +12 more locations on ClinicalTrials.gov
Collaborators
ADIENNE S.r.l. S.U.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02411084 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE4NCT06824103Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University